Aura Q3: CoMpass Treatment Complete, $297M Cash Into 1H 2029, CDMO Deal Signed
AURA sits 39% above its 52-week low of $4.73.
Summary
Aura reported Q3 2026 results with all 108 CoMpass patients done with treatment, topline data still guided to 2H 2027, a new CDMO manufacturing deal, and $297.2M in cash funding operations into 1H 2029.
Key Events · Earnings and Guidance · AURA
-
CoMpass Treatment Phase Complete
All 108 participants in the Phase 3 CoMpass trial of bel-sar in early choroidal melanoma have completed their treatment regimen and entered the 24-month follow-up; topline data from the 15-month primary endpoint remain on track for 2H 2027 under an FDA SPA.
-
Cash Runway Into 1H 2029
Cash, cash equivalents and marketable securities totaled $297.2 million as of September 30, 2026, which the company says funds operations into the first half of 2029 — past the expected CoMpass readout.
-
Loss Widens on Phase 3 Costs
Q3 2026 net loss was $32.1 million versus $26.1 million a year earlier, with R&D up to $24.7 million from $22.2 million on CoMpass CRO costs and G&A up to $10.3 million from $5.7 million including $4.5 million of restructuring charges.
-
New CDMO Manufacturing Deal
Aura established a supply relationship with an industry-leading CDMO that includes manufacturing capacity designated for bel-sar development and commercial supply, intended to give long-term control over production scheduling.
Analysis · AURA · Life Sciences
The quarter's real news is operational: all 108 CoMpass patients have finished treatment, so the Phase 3 clock now runs only on the 24-month observation period toward 15-month primary endpoint topline data in 2H 2027. A new CDMO relationship with designated manufacturing capacity de-risks commercial supply ahead of a potential BLA. The balance sheet supports the wait — $297.2M in cash and securities funds operations into 1H 2029, well past the readout. Against that, the loss widened to $32.1M for the quarter from $26.1M, driven by Phase 3 CRO costs and $4.5M of restructuring charges from the completed 20% workforce reduction. The next scheduled disclosure point is the December 8, 2026 early choroidal melanoma virtual event.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AURA was trading at $6.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $680.3M. The 52-week trading range was $4.73 to $9.54. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.